Standout Papers
- Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis (2022)
- Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis (2012)
- Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis (2017)
- Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors (2017)
- Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study (2017)
- Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study (2021)
Immediate Impact
2 by Nobel laureates 18 from Science/Nature 77 standout
Citing Papers
Atopic dermatitis
2025 Standout
JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma
2024 StandoutScience
Works of Keith S. Kanik being referenced
Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
2012 Standout
Phase IIb dose‐ranging study of the oral JAK inhibitor tofacitinib (CP‐690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease‐modifying antirheumatic drugs
2011
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Keith S. Kanik | 3174 | 1636 | 1754 | 50 | 4.9k | |
| Aileen L. Pangan | 3888 | 1941 | 1935 | 93 | 5.2k | |
| Sriram Krishnaswami | 3869 | 2141 | 1393 | 59 | 6.0k | |
| C. Birbara | 3705 | 1738 | 1875 | 42 | 5.4k | |
| Thasia Woodworth | 4066 | 1481 | 2293 | 84 | 7.3k | |
| Sudha Visvanathan | 3430 | 1658 | 2433 | 67 | 5.3k | |
| David Gruben | 4337 | 2471 | 1464 | 99 | 6.2k | |
| Maria Greenwald | 2671 | 1127 | 1416 | 74 | 5.0k | |
| Ronald Pedersen | 3352 | 1639 | 1319 | 66 | 4.6k | |
| Elliot Chartash | 2924 | 1479 | 1383 | 48 | 4.6k | |
| Mary Chester Wasko | 3319 | 1231 | 957 | 62 | 4.9k |
All Works
Loading papers...